Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Federation Francophone de Cancerologie Digestive
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Metastatic disease
At least one mesurable lesion according to RECIST V1.1 criteria
No prior chemotherapy (excepted if there is at least on lestion out of the irradition area)
Age \> 18 years. A favorable adviced by an onco geriatrician would be mandatory for inclusion of patients older than 75 older
Performance statut (WHO) 0-1
Polynyclear ≥ 1500/mm3
Bilirubine ≤ 1,5 fois la LSN, creatinin \< 120μmol / L
Signed informed consent form
You may not be if
Another type of pancreas tumor, as endocrine tumor ou with acinous cells
Ampulloma
Cerebral or meningeal metastasis
Gilbert disease
Neuropathie \> or = grade 1
Study treatments contraindication
Uncontrolled diarrhoea or inflamatory disease of colon or rectum, or bowel obstruction or bowel sub-obstruction no resolved with specific treatment
Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease prevent patient to receive study Cancer within the 5 years before inclusion, except for int situ cancer of the neck of the uterus or basal cell skin cancer
Significant previous cardiac and respiratory disease
Patient included in an other therapeutic study with experimental treatment
Pregnancy or breast feeding
Patient depreved of freedom or under gardianship
Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Clareo Health | First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
